13.6

Conclusion

The field of nanodrugs hold immense potential for treating diseases. Nanotechnol-

ogy confers significant benefits to medicine, targeted delivery of drugs to specific

tissues being the most important one. Nanodrugs not only improve the therapeutic

index of the drugs by increasing solubility but also reduce their off-target side

effects. Several preclinical researches have demonstrated the inherent prospects of

nanomedicines in treating renal diseases. Nephrolithiasis is among the chronic

kidney diseases which is a painful disorder and needs to be addressed with more

effective therapeutic options. An expanding group of nanomaterials are present that

can find implications in treatment of nephrolithiasis. In this review, we highlighted

various types of NPs and their properties that could be applied for the treatment of

kidney stones. We have also discussed the various challenges in the development of

nanodrugs for nephrolithiasis and the current research that has been conducted in this

regard.

Acknowledgments The authors are grateful to the Department of Biotechnology, Himachal

Pradesh University, Shimla, for the providing various resources. They are also thankful to the

Department of Biotechnology, Government of India, for providing the necessary support.

Conflict of Interest Further, the authors have no conflict of interest among themselves at their

place of work or with the institution.

References

Chauhan N, Hooda V, Pundir CS (2013) In vitro effects of metal oxide nanoparticles on barley

oxalate oxidase. J Nanopart Res 15:1493. https://doi.org/10.1007/s11051-013-1493-9

Chen H, Wang GD, Tang W, Todd T, Zhen Z, Tsang C, Hekmatyar K, Cowger T, Hubbard R,

Zhang W, Stickney J, Shen B, Xie J (2014) Gd-encapsulated carbonaceous dots with efficient

renal clearance for magnetic resonance imaging. Adv Mater 26:6761–6766

Das P, Kumar K, Nambiraj A, Rajan R, Awasthi R, Dua HM (2017) Potential therapeutic activity of

Phlogacanthus thyrsiformis Hardow (Mabb) flower extract and its biofabricated silver

nanoparticles against chemically induced urolithiasis in male Wistar rats. IJBM 103:621–629.

https://doi.org/10.1016/j.ijbiomac.2017.05.096

Duncan R, Gaspar R (2011) Nanomedicine(s) under the microscope. Mol Pharm 8:2101–2141

Dunwell JM, Purvis AS (2004) Cupins: the most functionally diverse protein superfamily? Phyto-

chemistry 65:7–17

Eaton DC, Pooler J (2013) Vander’s renal physiology, 8th edn. McGraw-Hill Medical Publishing

Gupta S, Kanwar SS (2018) Phytomolecules for kidney stone treatment and management. Biochem

Anal Biochem 7:362

Gupta S, Kanwar SS (2020a) The influence of dysbiosis on kidney stones that risk up renal cell

carcinoma (RCC). Semin Cancer Biol 70:134–138. https://doi.org/10.1016/j.semcancer.2020.

06.011

Gupta S, Kanwar SS (2020b) Therapeutic applications of microbial enzymes in the management of

kidney stone diseases. In: Microbial enzymes: roles and applications in industries,

microorganisms for sustainability 11. https://doi.org/10.1007/978-981-15-1710-5_13

13

Nanodrugs: A Futuristic Approach for Treating Nephrolithiasis

211